- Home
- AORT vs GAM Comparison
AORT vs GAM Comparison
Compare AORT & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- GAM
- Stock Information
- Founded
- AORT 1984
- GAM 1927
- Country
- AORT United States
- GAM United States
- Employees
- AORT N/A
- GAM N/A
- Industry
- AORT Medical/Dental Instruments
- GAM Investment Managers
- Sector
- AORT Health Care
- GAM Finance
- Exchange
- AORT Nasdaq
- GAM Nasdaq
- Market Cap
- AORT 1.0B
- GAM 1.2B
- IPO Year
- AORT 1993
- GAM N/A
- Fundamental
- Price
- AORT $24.69
- GAM $50.61
- Analyst Decision
- AORT Strong Buy
- GAM
- Analyst Count
- AORT 5
- GAM 0
- Target Price
- AORT $31.40
- GAM N/A
- AVG Volume (30 Days)
- AORT 470.9K
- GAM 20.1K
- Earning Date
- AORT 05-05-2025
- GAM 01-01-0001
- Dividend Yield
- AORT N/A
- GAM 5.74%
- EPS Growth
- AORT N/A
- GAM N/A
- EPS
- AORT N/A
- GAM 11.67
- Revenue
- AORT $388,537,000.00
- GAM N/A
- Revenue This Year
- AORT $11.21
- GAM N/A
- Revenue Next Year
- AORT $10.77
- GAM N/A
- P/E Ratio
- AORT N/A
- GAM $3.95
- Revenue Growth
- AORT 9.76
- GAM N/A
- 52 Week Low
- AORT $19.36
- GAM $37.32
- 52 Week High
- AORT $32.33
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- AORT 42.53
- GAM 47.65
- Support Level
- AORT $23.69
- GAM $50.01
- Resistance Level
- AORT $25.02
- GAM $51.53
- Average True Range (ATR)
- AORT 0.58
- GAM 0.59
- MACD
- AORT 0.25
- GAM 0.10
- Stochastic Oscillator
- AORT 83.02
- GAM 61.02
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.